Table 2.
A list of miRNA-inhibitors examined for their cancer therapeutic potential in pre-clinical studies*
| miRNA | Year | Delivery system | Cancer | Mechanism | Target | Model | Ref | |
|---|---|---|---|---|---|---|---|---|
| miR-10b | 2012 | Nanoparticles | Breast | Wound healing reduction | RHOC | In vitro | Cell line | [192] |
| miR-21 | 2012 | Solid lipid nanoparticles | Lung | Proliferation and invasion reduction | - | In vitro | Cell line | [94] |
| miR-155 | 2012 | Nanoparticles | Lymphoma | Tumor growth reduction | - | In vivo | Xenograft | [89] |
| miR-21 | 2013 | Lentiviral vector | Pancreatic | Proliferation and angiogenesis reduction | RhB | In vivo | Xenograft | [93] |
| miR-155 | 2013 | Polymer carrier | Leukemia | LIN28 increased and RUNX1 inhibited | LIN28, RUNX 1 | In vivo | Cell line | [193] |
| miR-520d-3p | 2013 | Nanoparticles | Ovarian | Proliferation and migration suppression | EPHB2 | In vivo | Orthotopic | [194] |
| miR-211 | 2014 | LNA | Multiple myeloma | Tumor growth suppression | p27Kip 1 | In vivo | Orthotopic | [195] |
| miR-31 | 2015 | LNA | Esophageal | Tumor formation and proliferation suppression | STK40 | In vivo | Zinc-deficient model | [97] |
| miR-126 | 2015 | Nanoparticles | Leukemia | Targeting leukemia stem cells | - | In vivo | Tail vein | [196] |
| miR-214 | 2015 | LNA | Colorectal cancer | Inflammation and tumor formation suppression | PDLM 2, PTEN | In vivo | DSS-AOM | [98] |
| miR-155 | 2015 | pHLIP | Lymphoma | Tumor growth suppression | BACH1 | In vivo | miR-155 transgenic mouse | [44] |
| miR-17 | 2017 | Nanoparticles | Liver | Tumor growth suppression | TGFBR 2 | In vivo | Xenograft | [197] |
| miR-21 | 2017 | Nanoparticles | Breast | Drug resistance reduction | - | In vivo | Xenograft | [198] |
| miR-21 | 2018 | Nanocarriers | Breast | Proliferation suppression | - | In vivo | Xenograft | [199] |
| miR-21 | 2018 | Nanoparticles | Ovarian | Drug resistance reduction | - | In vitro | Cell line | [200] |
| miR-21 | 2018 | Nanoparticles | Liver | Drug resistance reduction | - | In vivo | Xenograft | [201] |
| miR-21 and 10b | 2018 | Nanoparticles | Brain | Cell cycle arrest enhancement | - | In vivo | Xenograft | [202] |
| miR-214 | 2018 | Exosomes | Stomach | Drug resistance reduction | - | In vivo | Tail vein | [203] |
| miR-221 | 2018 | Nanoparticles | Leukemia | Tumorigenicity suppression | p27Kip | In vivo | Metastasis model | [204] |
| miR-21 | 2019 | Nanoparticles/LNA | Breast | Migration suppression | PTEN, PDCD4 | In vivo | Xenograft | [205] |
| miR-204 | 2019 | Nanoparticles | Ovarian | Angiogenesis suppression | THBS1 | In vivo | Orthotopic tumor | [206] |
*
Chronologically listed